Abstracts tagged "Behcet’s syndrome and uveitis"

Abstract Number: 1692 • 2019 ACR/ARP Annual Meeting
Long-Term Follow-Up of Anti-IL6-Receptor Tocilizumab in Refractory Uveitis in Patients with Behçet Disease: Multicenter Study of 14 Patients in Clinical Practice
Iñigo Gonzalez-Mazon¹, Lara Sanchez-Bilbao ², Belén Atienza-Mateo ², Jose Luis Martín-Varillas ², DIANA PRIETO- PENA ¹, Vanesa Calvo-Río ³, Rosalia Demetrio ⁴, Natalia Palmou-Fontana ¹, Javier Loricera ⁵, Emma Beltrán Catalán ⁶, Marisa Hernández Garfella ⁷, Elia Valls-Pascual ⁸, Antonio Atanés ⁹, Miguel Cordero Coma ⁹, Joan M Nolla ¹⁰, Carmen carrasco-Cubero ¹¹, Julio Sánchez ¹², Miguel A Gonzalez-Gay ² and Ricardo Blanco ², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵H.U. Marques de Valdecilla, Santander, Spain, ⁶Hospital del Mar, Barcelona, Spain, ⁷H.G.U. Valencia, Valencia, ⁸Dr Peset University Hospital, Valencia, Spain, ⁹HUAC La Coruña, Coruña, Spain, ¹⁰Hospital Universitari de Bellvitge, Hospitalet, Spain, ¹¹CHU de Badajoz, Badajoz, Spain, ¹²Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: Ocular involvement in Behçet’s disease (BD) is a potential severe and disabling complication. Anti-TNF-α agents have shown an improvement of visual outcome in BD-related…
Abstract Number: 2761 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Parenchymal Neurological Involvement in Behcet’s Syndrome Patients with Panuveitis
Berivan Bitik¹, Berna Goker², Kubilay Sahin³, Yesim Sucullu Karadag⁴, Ridvan Mercan⁵, Abdurrahman Tufan¹, Mehmet Akif Ozturk¹, Fikri Ak⁴, Yasar Karaaslan^6,7 and Seminur Haznedaroglu¹, ¹Internal Medicine-Rheumatology, Gazi University School of Medicine, Ankara, Turkey, ²Department of Internal Medicine- Rheumatology, Gazi University School of Medicine, Ankara, Turkey, ³Rheumatology, Ankara Numune Education and Research Hospital, Ankara, Turkey, ⁴Neurology, Ankara Numune Education and Research Hospital, Ankara, Turkey, ⁵Gazi University School of Medicine, Ankara, Turkey, ⁶Rheumatology, Hitit University, Corum, Turkey, ⁷Ankara Numune Training and Research Hospital, Ankara, Turkey
Background/Purpose Behcet’s Syndrome (BS) is a systemic vasculitis which may involve multiple organ systems simultaneously. Most frequently, clinical findings in BS fit into well recognized…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.